Genetic markers that could influence clinical decision making during treatment with methotrexate

Pharmacogenomics. 2020 Jun;21(8):505-507. doi: 10.2217/pgs-2019-0188. Epub 2020 Apr 28.

Authors

Patricia Esperon¹, Andrea Giletti¹

Affiliation

¹ Molecular Genetics Laboratory, Clinical Biochemistry Department, School of Chemistry, Universidad de la República, Montevideo, 11200, Uruguay.

PMID: 32342716
DOI: 10.2217/pgs-2019-0188

No abstract available

Keywords: efficacy; methotrexate; pharmacogenomic markers; toxicity.

Publication types

Editorial

MeSH terms

Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / therapeutic use
Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use
Clinical Decision-Making / methods*
Genetic Markers / drug effects
Genetic Markers / genetics*
Humans
Methotrexate / adverse effects
Methotrexate / therapeutic use*
Pharmacogenetics / methods*

Substances

Antimetabolites, Antineoplastic
Antirheumatic Agents
Genetic Markers
Methotrexate